Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Split-course SBRT with gemcitabine + nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer
ChiCTR1900024345Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and paclitaxel in pancreatic cancer (PC), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR1900024345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024345.